Biosplice Therapeutics
Biosplice Therapeutics is an American pharmaceutical company engaged in the development of alternative splicing technologies. Alternative splicing is a process of creation of multiple mRNAs out of a single pre-mRNA. The company asserts that medicines that can harness this process will help cure musculoskeletal, ummune and oncological disorders. Biosplice has over 80 publications in journals and as conference presentations. The company is headquartered in San Diego, California.
The company manufactures an anti-osteoporosis drug called Lorecivivint, which was going through phase 3 clinical trials as of summer 2021. Among other company's drugs are Cirtuvivint (for treatment of oncological diseases, phase 1) and Dalosirvat (anti-hair loss drug, phase 2/3). The company is also on the preclinical stages of developing an anti-Alzheimer's disease drug.
NewsHeat chart
- Week
- Month
- Year
- Media news
- Corp news
The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice
Company Valuation
- Valuation
- Share Price
- Cumulative Funding
The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.
*** - To view the data, please log into your account or create a new one.
News related to Biosplice Therapeutics25
Biosplice Therapeutics Announces Initiation of Acute Myeloid ...
Biosplice Therapeutics Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute ...
https://finance.yahoo.com/news/biosplice-therapeutics-announces-initiation-acute-110000507.htmlBiosplice Therapeutics Announces Department of Defense (DoD ...
Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program · About ...
https://markets.businessinsider.com/news/stocks/biosplice-therapeutics-announces-department-of-defense-dod-award-to-fund-collaboration-with-the-roskamp-institute-to-advance-its-neurology-program-1033147516Biosplice Therapeutics Announces Department of Defense (DoD ...
Yahoo · Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program....
https://finance.yahoo.com/news/biosplice-therapeutics-announces-department-defense-183600525.htmlCIO Leadership: Opportunities for Female Tech Leaders to Foster ...
CIOs and business technology executives at this event will also discuss how men...
https://www.streetinsider.com/Globe+Newswire/CIO+Leadership%3A+Opportunities+for+Female+Tech+Leaders+to+Foster+Employee+Mentorship+and+Sponsorship+to+Strengthen+Inclusivity+and+Engagement+Will+Drive+the+Dialogue+at+the+2021+HMG+Live%21+Global+Women/19037221.htmlWeek in review: Everest announces 2 in-licensings with total value ...
Shanghai Everest Medicines in-licensed a BTK inhibitor for renal diseases from Sinovent and SinoMab Bio for $561 mln. Cue Health filed for a $180 mln IPO ...
https://seekingalpha.com/article/4456091-week-in-review-everest-announces-2-in-licensings-with-value-of-1-billion